Carregant...
Is It the Twilight of BACE1 Inhibitors?
β-secretase (BACE1) has been regarded as a prime target for the development of amyloid beta (Aβ) lowering drugs in the therapy of Alzheimer´s disease (AD). Although the enzyme was discovered in 1991 and helped to formulate the Aβ hypothesis as one of the very important features of AD etiopathogenesi...
Guardat en:
| Publicat a: | Curr Neuropharmacol |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Bentham Science Publishers
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7903497/ https://ncbi.nlm.nih.gov/pubmed/32359337 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2174/1570159X18666200503023323 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|